We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.69%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$714M
AUM Growth
-$199M
Cap. Flow
+$8.81M
Cap. Flow %
1.23%
Top 10 Hldgs %
30.92%
Holding
97
New
3
Increased
39
Reduced
32
Closed
12

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$10.8M
2
ABBV icon
AbbVie
ABBV
+$10.2M
3
CVS icon
CVS Health
CVS
+$8M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.61M
5
UNH icon
UnitedHealth
UNH
+$6.05M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$10.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.1M
4
HUM icon
Humana
HUM
+$7.42M
5
BDX icon
Becton Dickinson
BDX
+$5.06M

Sector Composition

Rank Sector Weight
1 Healthcare 96.22%
2 Energy 0.06%
3 Technology 0.03%
4 Financials 0.02%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$29.6M 4.15%
1,000,000
+225,000
+29% +$7.61M
VRTX icon
2
Vertex Pharmaceuticals
VRTX
$120B
$27.4M 3.83%
115,000
-45,000
-28% -$10.3M
ABBV icon
3
AbbVie
ABBV
$434B
$25.1M 3.52%
330,000
+120,000
+57% +$10.2M
NVCR icon
4
NovoCure
NVCR
$1.77B
$24.2M 3.4%
360,000
+10,000
+3% +$790K
UNH icon
5
UnitedHealth
UNH
$378B
$19.9M 2.79%
80,000
+22,000
+38% +$6.05M
BMY icon
6
Bristol-Myers Squibb
BMY
$132B
$19.5M 2.73%
350,000
+10,000
+3% +$611K
NKTR icon
7
Nektar Therapeutics
NKTR
$2.33B
$19.2M 2.69%
71,667
-1,666
-2% -$515K
ESPR
8
DELISTED
Esperion Therapeutics
ESPR
$18.7M 2.62%
592,798
-67,202
-10% -$3.55M
CI icon
9
Cigna
CI
$74.7B
$18.6M 2.61%
105,000
+10,000
+11% +$1.94M
BSX icon
10
Boston Scientific
BSX
$71.8B
$18.4M 2.58%
565,000
+113,332
+25% +$4.43M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.6B
$15.6M 2.19%
184,845
-25,155
-12% -$2.17M
CVS icon
12
CVS Health
CVS
$134B
$15.4M 2.16%
260,000
+119,786
+85% +$8M
ELV icon
13
Elevance Health
ELV
$82.3B
$14.8M 2.07%
65,000
+3,000
+5% +$818K
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
$14.4M 2.01%
160,000
+18,681
+13% +$1.83M
HUM icon
15
Humana
HUM
$44.3B
$14.1M 1.98%
45,000
-22,000
-33% -$7.42M
LLY icon
16
Eli Lilly
LLY
$995B
$13.9M 1.94%
100,000
-11,446
-10% -$1.57M
ABT icon
17
Abbott
ABT
$185B
$13.4M 1.88%
170,000
-37,469
-18% -$3.13M
ABMD
18
DELISTED
Abiomed Inc
ABMD
$12.8M 1.79%
88,000
+1,000
+1% +$166K
MRK icon
19
Merck
MRK
$314B
$12.7M 1.78%
172,920
+5,240
+3% +$412K
GH icon
20
Guardant Health
GH
$21.6B
$12.2M 1.71%
175,000
+19,732
+13% +$1.51M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.8B
$12M 1.68%
120,000
+19,195
+19% +$2.48M
AXNX
22
DELISTED
Axonics, Inc. Common Stock
AXNX
$11.8M 1.66%
465,000
+135,000
+41% +$4.01M
MDT icon
23
Medtronic
MDT
$110B
$11.8M 1.65%
130,780
+5,750
+5% +$612K
ISRG icon
24
Intuitive Surgical
ISRG
$134B
$11.4M 1.6%
69,000
+33,000
+92% +$6.04M
NBIX icon
25
Neurocrine Biosciences
NBIX
$16.9B
$11.3M 1.58%
130,000
+10,000
+8% +$979K
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rhenman & Partners Asset Management held 97 positions worth $714M, down 22% from $913M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2020 filing shows 3 new, 39 increased, 32 reduced and 12 closed positions. Its largest new stake was Zimmer Biomet: 82,400 shares worth $8.09M. The largest sale was Dermira, Inc., an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Energy and Technology.

  • Rhenman & Partners Asset Management's largest Q1 2020 buy was Zimmer Biomet: 82,400 shares worth $8.09M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q1 2020, an estimated $10.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $10.3M.
  • Rhenman & Partners Asset Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $12.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $714M portfolio in Q1 2020.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 12 in Q1 2020.
  • Rhenman & Partners Asset Management's portfolio value fell 22% quarter-over-quarter to $714M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2020, filed 16 Apr 2020.